Kairos Pharma, Ltd. (KAPA) Stock Analysis & Investment Frameworks
Kairos Pharma, Ltd. (KAPA) stock analysis on Invetso. Review Kairos Pharma, Ltd.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
Kairos Pharma, Ltd. Company Overview
- Exchange: New York Stock Exchange Arca
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
Kairos Pharma, Ltd. Key Financial Metrics
- Market Cap: $2.04M
- Revenue: $N/A
- ROE: -98.77%
- ROIC: -143.93%
- Dividend Yield: N/A
About Kairos Pharma, Ltd.
Kairos Pharma, Ltd. operates as a clinical-stage biopharmaceutical company focused on developing innovative treatments for individuals battling cancer. Its therapeutic portfolio includes a range of antibodies and small molecules engineered to combat various malignancies, such as prostate, lung, and breast cancer, as well as glioblastoma. Initially incorporated in 2013 under the name NanoGB13, Inc., the enterprise officially adopted its current identity as Kairos Pharma, Ltd. in July 2016. The company's operations are headquartered in Los Angeles, California.
Kairos Pharma, Ltd. Investment Frameworks
Invetso analyzes Kairos Pharma, Ltd. (KAPA) across the following frameworks:
- Kairos Pharma, Ltd. 10Y Growth Potential
- Kairos Pharma, Ltd. Scenario Analysis
- Kairos Pharma, Ltd. Risks & Opportunities
- Kairos Pharma, Ltd. Economic Moat
- Kairos Pharma, Ltd. Business Model
- Kairos Pharma, Ltd. Management
- Kairos Pharma, Ltd. SWOT Analysis
- Kairos Pharma, Ltd. Porter's 5 Forces
- Kairos Pharma, Ltd. PESTLE Analysis
- Kairos Pharma, Ltd. ESG Analysis